Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 6/20 | 0.78 |
| ▸ | RAB9A | P51151 | 5/20 | 0.78 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.70 |
| ▸ | LMNA | P02545 | 3/20 | 0.70 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.70 |
| ▸ | MAPT | P10636 | 3/20 | 0.68 |
| ▸ | CNR1 | P21554 | 1/20 | 0.67 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.64 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.64 |
| ▸ | HTT | P42858 | 2/20 | 0.62 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.61 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.61 |
| ▸ | EPAS1 | Q99814 | 2/20 | 0.61 |
| ▸ | MEN1 | O00255 | 2/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.61 |
| ▸ | POLB | P06746 | 1/20 | 0.61 |
| ▸ | HPGD | P15428 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4915213 | 0.89 | CNR1 (0.72) | NPC1RAB9ASMN1; SMN2LMNAMAPK1 | |
| SCHEMBL28648364 | 0.88 | RAB9A (1.00) | NPC1RAB9ASMN1; SMN2LMNAMAPK1 | |
| SCHEMBL21024443 | 0.88 | RAB9A (1.00) | NPC1RAB9ASMN1; SMN2LMNAMAPK1 | |
| Hydrochloric Acid SCHEMBL31072329 | 0.87 | RAB9A (0.97) | NPC1RAB9ASMN1; SMN2LMNAMAPK1 | |
| Hydrochloric Acid SCHEMBL31072328 | 0.87 | RAB9A (0.97) | NPC1RAB9ASMN1; SMN2LMNAMAPK1 | |
| Hydrochloric Acid SCHEMBL31072327 | 0.87 | RAB9A (0.97) | NPC1RAB9ASMN1; SMN2LMNAMAPK1 | |
| SCHEMBL4998852 | 0.86 | HRH3 (0.64) | NPC1RAB9ASMN1; SMN2MAPK1HRH3 | |
| SCHEMBL4922787 | 0.85 | NPC1 (0.65) | NPC1RAB9ASMN1; SMN2LMNAMAPK1 | |
| SCHEMBL15932601 | 0.84 | NPC1 (0.69) | NPC1RAB9ASMN1; SMN2MAPK1HRH3 | |
| SCHEMBL24024131 | 0.83 | RAB9A (0.91) | NPC1RAB9ASMN1; SMN2LMNAMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120214808-A1 | Aryl Urea Derivatives for Treating Obesity | PROSIDION LIMITED (GB) | 2012-08-23 | — | — | US | claimed |
| US-20080261952-A1 | Aryl Urea Derivatives for Treating Obesity | PROSIDION LTD. (GB) | 2008-10-23 | — | — | US | claimed |
| US-20120214808-A1 | Aryl Urea Derivatives for Treating Obesity | PROSIDION LIMITED (GB) | 2012-08-23 | — | — | US | disclosed |
| US-20080261952-A1 | Aryl Urea Derivatives for Treating Obesity | PROSIDION LTD. (GB) | 2008-10-23 | — | — | US | disclosed |
| EP-1786422-A2 | ARYL UREA DERIVATIVES FOR TREATING OBESITY | Prosidion Limited (GB) | 2007-05-23 | — | — | EP | disclosed |
| WO-2006018662-A2 | ARYL UREA DERIVATIVES FOR TREATING OBESITY | PROSIDION LIMITED (GB) | 2006-02-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080261952-A1 | Aryl Urea Derivatives for Treating Obesity | CNR1, GPR119, UTS2R | NPC1 148/4885RAB9A 3359/4885SMN1; SMN2 3931/4885 |
| US-20120214808-A1 | Aryl Urea Derivatives for Treating Obesity | CNR1, GPR119, UTS2R | NPC1 148/4885RAB9A 3359/4885SMN1; SMN2 3931/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.